Vivex Biomedical Raised $6.6MM in Series A Funding

By Julie A. Vetalice

Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company's biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.

Sources: Form D, SEC.gov; vivex.com

The company raised $7.4MM in its last round of funding, in 2013.

Product Labels: Bone Graft Materials/DBM, Synthetic Bone Graft